A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report-Reference-Cited by-同舟云学术

A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report

Published:2020-02-03 Issue:1 Volume:15 Page:69-72
ISSN:1574-8863
Container-title:Current Drug Safety
language:en
Short-container-title:CDS

Author:

Dastoli Stefano¹,Iannone Luigi Francesco²,Bennardo Luigi¹^ORCID,Silvestri Martina¹^ORCID,Palleria Caterina²,Nisticò Steven Paul¹^ORCID,De Sarro Giovambattista²^ORCID,Russo Emilio²^ORCID

Affiliation:

1. Department of Health Sciences, Unit of Dermatology, Magna Graecia University, Catanzaro, Italy

2. Department of Health Sciences, Unit of Pharmacology, Magna Graecia University, Catanzaro, Italy

Abstract

Background: Psoriasis is a cutaneous inflammatory condition characterized by an altered turnover of keratinocytes leading to scaly patches. Secukinumab and ixekizumab are two biologic drugs inhibiting interleukin-17. Objective: We report the first case, according to Naranjo score, of a secukinumab-induced erectile dysfunction with severe plaque psoriasis that disappeared after switching to another anti IL17 drug (ixekizumab). Methods: A 45 years old man experienced erectile dysfunction during treatment with an anti-IL17. The adverse effect appeared after 60 days of treatment with secukinumab and rapidly disappeared after discontinuation of the drug. All necessary urologic exams were carried out. Re-administration of secukinumab, due to the exacerbation of psoriasis, caused the same sexual dysfunction after 60 days. Results: Switching to ixekizumab lead to a resolution of the erectile dysfunction and a complete skin clearance. Conclusion: We describe for the first time a sexual dysfunction possibly due to secukinumab and its resolution after the switch to another similar but different drug, highlighting the potential difference between anti-IL17A drugs.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),Pharmacology,Toxicology

Reference16 articles.

1. Greb J.E.; Goldminz A.M.; Elder J.T.; Psoriasis. Nat Rev Dis Primers 2016,2,16082

2. Loos A.M.; Liu S.; Segel C.; Ollendorf D.A.; Pearson S.D.; Linder J.A.; Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis. J Am Acad Dermatol 2018,79(1),135-144.e7

3. Campa M.; Mansouri B.; Warren R.; Menter A.; A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther (Heidelb) 2016,6(1),1-12

4. Antonelli M.; Khan M.A.; Magrey M.N.; Differential adverse events between TNF-α inhibitors and IL-17 axis inhibitors for the treatment of spondyloarthritis. Curr Treatm Opt Rheumatol 2015,1(2),239-254

5. Conti A; Peccerillo F; Amerio P; Efficacy and safety of switching to ixekizumab in secukinumab nonresponder psoriatic patients: Results from a multicenter experience. 2019,180(6),1547-8

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database;Expert Opinion on Drug Safety;2024-08-27

2. A Rare Case of Drug-induced Erectile Dysfunction with Adalimumab and Certolizumab Solved after Switch to Ustekinumab in a Crohn's Disease Patient;Current Drug Safety;2023-08

3. A Review of the Safety of Interleukin-17A Inhibitor Secukinumab;Pharmaceuticals;2022-11-07

4. Review of dermatologic medications and impact on male fertility, sexual dysfunction and teratogenicity;Andrology;2022-08-03

5. Review of secukinumab‐induced adverse events of special interest and its potential pathogenesis;Dermatologic Therapy;2022-06-08